Since Zepbound was approved by the FDA to treat obesity in late 2023, its maker Eli Lilly has been steadily closing in on fierce rival Novo Nordisk’s early lead in the obesity market.

The Houston-based Empower Pharmacy is seeking to dismiss a lawsuit that targets its ability to sell popular diabetes and ...

Eli Lilly slashed ... that the global GLP-1 market will expand at a compound annual growth rate (CAGR) of 21.6% from 2024 to 2030. Considering that the TAM for Zepbound is set to continue growing ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

First of all, I think Lilly's Zepbound strategy is brilliant. It should open up a larger market for the company's obesity drug. As James Zervos, chief operating officer with Obesity Action ...

Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both have witnessed rapid demand despite being on the market for less than ...

Zepbound’s superior efficacy and strategic market expansion suggest ... and it seems that Eli Lilly has followed in some way Novo Nordisk’s strategy to increase patients’ population through ...

‘#Obesity Market Shift? #Eli_Lilly's #Zepbound could overtake #Novo ... that Eli Lilly has followed in some way Novo Nordisk’s strategy to increase patients’ population through investigating ...

New Delhi: Eli Lilly’s Zepbound drug holds potential to dominate the global obesity market due to its superior ... in some way Novo Nordisk’s strategy to increase patients’ population ...

People taking Zepbound lost 20.2% of their body weight on average after 72 weeks of treatment in the Lilly-sponsored study, compared with a 13.7% loss for Wegovy patients, Lilly said Wednesday.

Eli Lilly said on Wednesday patients taking its obesity drug Zepbound lost 47% more weight than those who were given Novo Nordisk's Wegovy in the first large, head-to-head trial of the highly in ...